Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGPL1 | O95470 | 3/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 6/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076094 | 1.00 | SGPL1 (0.39) | SGPL1CXCR3DGAT1RETNR1H2 | |
| SCHEMBL12264577 | 0.89 | SGPL1 (0.41) | SGPL1CXCR3NR1H2NR1H3LMNA | |
| SCHEMBL4249119 | 0.88 | MAOB (0.45) | SGPL1CXCR3RETSMOMAOB | |
| SCHEMBL13590946 | 0.88 | MAOB (0.45) | SGPL1CXCR3RETSMOMAOB | |
| SCHEMBL13590947 | 0.88 | MAOB (0.45) | SGPL1CXCR3RETSMOMAOB | |
| SCHEMBL1073690 | 0.87 | SGPL1 (0.40) | SGPL1CXCR3DGAT1RETNR1H2 | |
| SCHEMBL1073689 | 0.87 | SGPL1 (0.40) | SGPL1CXCR3DGAT1RETNR1H2 | |
| SCHEMBL1075901 | 0.86 | SGPL1 (0.42) | SGPL1CXCR3RETNR1H2NR1H3 | |
| SCHEMBL1075904 | 0.86 | SGPL1 (0.42) | SGPL1CXCR3RETNR1H2NR1H3 | |
| SCHEMBL4251784 | 0.86 | SGPL1 (0.39) | SGPL1CXCR3DGAT1RETNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263610-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2011-10-27 | — | — | US | claimed |
| EP-2274302-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2011-01-19 | — | — | EP | claimed |
| WO-2009123948-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-10-08 | — | — | WO | claimed |
| US-20110263610-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| EP-2274302-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009123948-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263610-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | SGPL1 656/4885CXCR3 1268/4885DGAT1 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.